| Literature DB >> 28494532 |
Shu-Hui Wang1,2, Ching-Chi Chi3,4, Zi-Hao Zhao1, Tao-Hsin Tung5,6.
Abstract
PURPOSE: Previous western studies have found Caucasians with skin cancer, either melanoma or nonmelanoma skin cancer (NMSC), have an elevated risk of second primary cancer. Our objective was to assess the risk of second primary cancer in Taiwanese with NMSC.Entities:
Keywords: Charlson comorbidity index; Non-melanoma skin cancer; Population-based study; Second primary neoplasms
Mesh:
Year: 2017 PMID: 28494532 PMCID: PMC5912144 DOI: 10.4143/crt.2017.110
Source DB: PubMed Journal: Cancer Res Treat ISSN: 1598-2998 Impact factor: 4.679
Fig. 1.Flow chart of selection of the study population. NMSC, non-melanoma skin cancer.
Characteristics and potential confounders of the study subjects
| Control (n=2,020) | Non-melanoma skin cancer group (n=505) | p-value | |
|---|---|---|---|
| Women | 1,024 (80.0) | 256 (20.0) | 1.000 |
| Men | 996 (80.0) | 249 (20.0) | |
| 67.2±15.2 | 67.2±15.4 | 0.96 | |
| City | 893 (44.2) | 223 (44.2) | 1.000 |
| Suburbs | 747 (37.0) | 187 (37.0) | |
| Village | 380 (18.8) | 95 (18.8) | |
| 3.3±2.7 | 4.7±3.2 | < 0.001 | |
| 6.0±3.0 | 5.7±3.1 | 0.05 |
Values are presented as number (%) or mean±standard deviation.
Risk of second primary cancer in people with non-melanoma skin cancer
| No. | No. of incident second primary cancer | No. of person-years | Incidence (per 102 person-year) | Adjusted HR (95% CI)[ | |
|---|---|---|---|---|---|
| 2,525 | 188 | 14,931.71 | 1.26 (1.09-1.45) | - | |
| Control | 2,020 | 130 | 12,068.08 | 1.08 (0.90-1.27) | 1.00 (reference) |
| NMSC | 505 | 58 | 2,863.63 | 2.03 (1.55-2.59) | 1.43 (1.05-1.96) |
| 1,245 | 116 | 7,345.79 | 1.58 (1.31-1.88) | - | |
| Control | 1,129 | 80 | 5,972.34 | 1.34 (1.07-1.65) | 1.00 (reference) |
| NMSC | 116 | 36 | 1,373.45 | 2.62 (1.86-3.57) | 1.51 (1.01-2.25) |
| 1,280 | 72 | 7,585.93 | 0.95 (0.75-1.19) | - | |
| Control | 1,208 | 50 | 6,095.75 | 0.82 (0.61-1.07) | 1.00 (reference) |
| NMSC | 72 | 22 | 1,490.18 | 1.48 (0.94-2.18) | 1.35 (0.82-2.24) |
HR, hazard ratio; CI, confidence interval; NMSC, non-melanoma skin cancer.
Adjusted for age, sex, urbanization, and Charlson Comorbidity Index.
Fig. 2.Cumulative incidence curves of second primary cancer in people with non-melanoma skin cancer (NMSC). (A) All subjects. (B) Men. (C) Women.
Stratified analysis based on sex
| Second primary cancer | Men (n=1,245) | Women (n=1,280) | ||||
|---|---|---|---|---|---|---|
| No. (%) | Adjusted HR (95% CI)[ | No. (%) | Adjusted HR (95% CI)[ | |||
| Control (n=996) | NMSC (n=249) | Control (n=1,024) | NMSC (n=256) | |||
| Lip, oral cavity, and pharynx | 7 (0.7) | 6 (2.4) | 2.99 (1.00-9.10) | 1 (0.1) | 0 | - |
| Digestive organs and peritoneum | 33 (3.3) | 9 (3.6) | 0.88 (0.98-1.03) | 24 (2.3) | 3 (1.2) | 0.38 (0.11-1.26) |
| Colorectal | 14 (1.4) | 4 (1.6) | 0.93 (0.30-2.87) | 12 (1.2) | 1 (0.4) | 0.25 (0.03-1.96) |
| Respiratory and intrathoracic organs | 14 (1.4) | 3 (1.2) | 0.73 (0.21-2.57) | 4 (0.4) | 2 (0.8) | 1.46 (0.27-8.03) |
| Bone, articular cartilage, connective, and other soft tissue | 0 | 3 (1.2) | - | 2 (0.2) | 2 (0.8) | 2.85 (0.40-20.24) |
| Melanoma | 0 | 1 (0.4) | - | 0 | 3 (1.2) | - |
| Breast | 0 | 0 | - | 6 (0.6) | 5 (2.0) | 2.58 (0.79-8.50) |
| Genital | 10 (1.0) | 2 (0.8) | 0.76 (0.16-3.53) | 6 (0.6) | 1 (0.4) | 0.54 (0.06-4.49) |
| Genitourinary organs | 7 (0.7) | 7 (2.8) | 3.51 (1.21-10.17) | 2 (0.2) | 2 (0.8) | 3.21 (0.45-22.98) |
| Prostate | 9 (0.9) | 2 (0.8) | 0.86 (0.18-4.06) | - | - | - |
| Eyes | 0 | 1 (0.4) | - | 0 | 1 (0.4) | - |
| Brain and nervous system | 0 | 0 | - | 1 (0.1) | 0 | - |
| Thyroid gland and endocrine glands | 2 (0.2) | 0 | - | 1 (0.1) | 0 | - |
| Lymphatic and hematopoietic tissue | 5 (0.5) | 1 (0.4) | 0.7 (0.08-6.12) | 2 (0.2) | 0 | - |
NMSC, non-melanoma skin cancer; HR, hazard ratio; CI, confidence interval.
Adjusted for age, sex, urbanization, and Charlson Comorbidity Index.
Fig. 3.Cumulative incidence curves of second primary cancer involving the lip, oral cavity, pharynx (A), and the genitourinary organs (B) in men. NMSC, non-melanoma skin cancer.